Synergy CHC Files to Sell 101.71M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Synergy CHC files to sell 101.71M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNYR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNYR
Wall Street analysts forecast SNYR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.278
Low
5.00
Averages
6.00
High
7.00
Current: 0.278
Low
5.00
Averages
6.00
High
7.00
About SNYR
Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Synergy CHC Reports Q1 Loss with Revenue Decline
- Earnings Loss: Synergy CHC reported a Q1 GAAP EPS of -$0.23, indicating a significant decline in profitability that reflects intensified market competition and internal challenges.
- Revenue Decline: The company generated $5.49 million in revenue for Q1, down approximately 32.77% year-over-year, suggesting severe pressure on sales and market share that could impact future growth potential.
- Negative Adjusted EBITDA: Adjusted EBITDA stood at -$0.35 million compared to $1.98 million in Q1 2025, highlighting a significant drop in operational efficiency that may weaken investor confidence.
- Tightening Liquidity: Cash position fell to approximately $0.29 million from $2.62 million in December 2025, indicating increased liquidity risk for the company, which urgently needs to raise funds to sustain operations.
See More
Synergy CHC Reports FY 2025 Earnings Results
- Poor Earnings Performance: Synergy CHC reported a FY 2025 GAAP EPS of -$1.27, indicating significant challenges in profitability that could undermine investor confidence and affect stock performance.
- Revenue Decline: The company reported revenue of $30.38 million, a 12.8% year-over-year decrease, reflecting weak market demand and intensified competition, which may lead to uncertainties in future growth prospects.
- Quarterly Earnings Call Insights: During the Q4 2025 earnings call, management is expected to discuss specific factors contributing to the revenue decline and outline strategies to restore market confidence and improve performance.
- Historical Financial Data: Historical financial data for Synergy CHC indicates that ongoing losses and declining revenues may pose a threat to the company's long-term sustainability, prompting investors to closely monitor future financial performance and strategic adjustments.
See More
Synergy CHC Corp Reports Significant Q4 Losses Amid Revenue Decline
- Significant Revenue Decline: Synergy CHC Corp reported a Q4 net revenue of $6.07 million, a 41% decrease year-over-year, primarily due to a $2.5 million revenue reversal from the termination of an international license agreement, highlighting the company's vulnerability in international markets and reliance on revenue sources.
- Gross Margin Drop: The gross margin for Q4 fell to 36.6%, down from 63.3% in the same quarter last year, indicating severe challenges to profitability due to inventory write-offs and the impact of the license agreement termination, which may affect future investor confidence.
- Surge in Operating Expenses: Operating expenses surged to $15.53 million in Q4, up from $5.14 million in the prior year, driven by one-time items such as bad debt allowances and prepaid media credit write-offs, further exacerbating the company's financial burden.
- Widening Net Loss: The company reported a net loss of $14.82 million for Q4, a significant decline from a net income of $105,700 in the same quarter of the previous year, reflecting increased pressure in market competition and deteriorating financial health, which may raise investor concerns about future growth.
See More
Synergy CHC Corp. Updates Q4 and Full Year 2025 Financial Results Release Date
- Financial Reporting Schedule: Synergy CHC Corp. will release its fourth quarter and full year financial results for the period ending December 31, 2025, on April 1, 2026, before market open, ensuring timely access to critical financial information for investors.
- Conference Call Details: The company's CEO Jack Ross and CFO Jaime Fickett will host a conference call at 9:00 a.m. ET to provide detailed insights into the financial results, enhancing communication with investors.
- Webcast Availability: The conference call will be available via a live webcast on the company's Investor Relations section, allowing investors who cannot dial in to participate, thereby improving information transparency.
- Brand Market Performance: Synergy's brands, FOCUSfactor® and Flat Tummy®, continue to grow in major retailers across the U.S., Canada, Mexico, and the U.K., demonstrating the company's strong competitive position in the health and wellness product market.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
New Show Airing on Bloomberg Television
- Rich Program Content: Tonight's airing of 'New to The Street' on Bloomberg Television will showcase Virtuix's immersive technology platform, highlighting its rapid growth in consumer and defense markets, which is expected to attract a wide audience.
- International Expansion Update: YY Group will provide updates on its international expansion in Hong Kong, UAE, and Southeast Asia, showcasing AI-enabled workforce automation and strong revenue momentum, indicating its competitiveness in the premium client market.
- Strategic Acquisition Discussion: Roadzen's leadership will discuss its strategic acquisition plans and the scaling of its AI-driven auto insurance and claims ecosystem, demonstrating its innovative capabilities and market potential in the insurance industry.
- Fintech Strategy: Alphaton Capital will outline its fintech-driven investment strategy and capital markets positioning in an interview filmed at the New York Stock Exchange, enhancing its credibility and appeal among global investors.
See More
Synergy CHC Reports Q1 Loss with Revenue Decline
- Earnings Loss: Synergy CHC reported a Q1 GAAP EPS of -$0.23, indicating a significant decline in profitability that reflects intensified market competition and internal challenges.
- Revenue Decline: The company generated $5.49 million in revenue for Q1, down approximately 32.77% year-over-year, suggesting severe pressure on sales and market share that could impact future growth potential.
- Negative Adjusted EBITDA: Adjusted EBITDA stood at -$0.35 million compared to $1.98 million in Q1 2025, highlighting a significant drop in operational efficiency that may weaken investor confidence.
- Tightening Liquidity: Cash position fell to approximately $0.29 million from $2.62 million in December 2025, indicating increased liquidity risk for the company, which urgently needs to raise funds to sustain operations.
See More
Synergy CHC Reports FY 2025 Earnings Results
- Poor Earnings Performance: Synergy CHC reported a FY 2025 GAAP EPS of -$1.27, indicating significant challenges in profitability that could undermine investor confidence and affect stock performance.
- Revenue Decline: The company reported revenue of $30.38 million, a 12.8% year-over-year decrease, reflecting weak market demand and intensified competition, which may lead to uncertainties in future growth prospects.
- Quarterly Earnings Call Insights: During the Q4 2025 earnings call, management is expected to discuss specific factors contributing to the revenue decline and outline strategies to restore market confidence and improve performance.
- Historical Financial Data: Historical financial data for Synergy CHC indicates that ongoing losses and declining revenues may pose a threat to the company's long-term sustainability, prompting investors to closely monitor future financial performance and strategic adjustments.
See More
Synergy CHC Corp Reports Significant Q4 Losses Amid Revenue Decline
- Significant Revenue Decline: Synergy CHC Corp reported a Q4 net revenue of $6.07 million, a 41% decrease year-over-year, primarily due to a $2.5 million revenue reversal from the termination of an international license agreement, highlighting the company's vulnerability in international markets and reliance on revenue sources.
- Gross Margin Drop: The gross margin for Q4 fell to 36.6%, down from 63.3% in the same quarter last year, indicating severe challenges to profitability due to inventory write-offs and the impact of the license agreement termination, which may affect future investor confidence.
- Surge in Operating Expenses: Operating expenses surged to $15.53 million in Q4, up from $5.14 million in the prior year, driven by one-time items such as bad debt allowances and prepaid media credit write-offs, further exacerbating the company's financial burden.
- Widening Net Loss: The company reported a net loss of $14.82 million for Q4, a significant decline from a net income of $105,700 in the same quarter of the previous year, reflecting increased pressure in market competition and deteriorating financial health, which may raise investor concerns about future growth.
See More
Synergy CHC Corp. Updates Q4 and Full Year 2025 Financial Results Release Date
- Financial Reporting Schedule: Synergy CHC Corp. will release its fourth quarter and full year financial results for the period ending December 31, 2025, on April 1, 2026, before market open, ensuring timely access to critical financial information for investors.
- Conference Call Details: The company's CEO Jack Ross and CFO Jaime Fickett will host a conference call at 9:00 a.m. ET to provide detailed insights into the financial results, enhancing communication with investors.
- Webcast Availability: The conference call will be available via a live webcast on the company's Investor Relations section, allowing investors who cannot dial in to participate, thereby improving information transparency.
- Brand Market Performance: Synergy's brands, FOCUSfactor® and Flat Tummy®, continue to grow in major retailers across the U.S., Canada, Mexico, and the U.K., demonstrating the company's strong competitive position in the health and wellness product market.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
New Show Airing on Bloomberg Television
- Rich Program Content: Tonight's airing of 'New to The Street' on Bloomberg Television will showcase Virtuix's immersive technology platform, highlighting its rapid growth in consumer and defense markets, which is expected to attract a wide audience.
- International Expansion Update: YY Group will provide updates on its international expansion in Hong Kong, UAE, and Southeast Asia, showcasing AI-enabled workforce automation and strong revenue momentum, indicating its competitiveness in the premium client market.
- Strategic Acquisition Discussion: Roadzen's leadership will discuss its strategic acquisition plans and the scaling of its AI-driven auto insurance and claims ecosystem, demonstrating its innovative capabilities and market potential in the insurance industry.
- Fintech Strategy: Alphaton Capital will outline its fintech-driven investment strategy and capital markets positioning in an interview filmed at the New York Stock Exchange, enhancing its credibility and appeal among global investors.
See More
